Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...
On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...
Seamless Therapeutics inks research collaboration with Lilly to develop programmable recombinase-based therapeutics for hearing loss: Dresden, Germany Friday, January 30, 2026, 15 ...
Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results